Diabetes mellitus as an economic problem in Russian Federation

Objective.

To estimate annual expenditures attributed to diabetes mellitus (DM) per patient in Russia based on data from epidemiologic studies and to analyse DM cost drivers.

Methods.

The expenditures per diabetic patient were calculated as the sum of medical costs (outpatient and emergency room visits, inpatient care and medications provided during outpatient care), payments for sick leaves, disability pensions and gross domestic production (GDP) losses due to temporary disability (indirect costs). All data on resource consumption and productivity losses were derived from the dataset for Russia, collected from the point of view of a multicentre international study on the practice of DM treatment. Medication costs were based on registered governmental price lists (list of vital and essential drugs). Medical care costs were estimated using the approved public health care reimbursement rates. Disability payments were calculated on the basis of data published by the Russian Pension Fund and Social Security Fund. GDP losses were assessed using federal statistics.

Results.

The mean total annual costs per patient with DM type 1 (T1) were 81.1 thousand Russian rubles (RUR) and those per patient with DM type 2 (T2) were 70.8 thousand RUR. Although most patients with DMT2 were >60 years, approximately 25% of costs were nonmedical and caused by productivity losses; for patients with DM type 1(T1), this proportion was 35%. The medical cost structure differed depending on the type of diabetes. In T1, the main component was attributed to DM treatment; in DMT2, almost half of medical costs were due to DM complications. Medication costs accounted for 69% and inpatient care accounted for only 22% of medical costs in DMT1. For DMT2, the proportion spent on inpatient care (43%) was almost equal to medication costs (46%). Mean expenditures per patient with DM complications were higher; in the case of DMT2, the presence of complications increased the costs by 3 times. Mean medical costs were higher for patients not reaching the target level of Hb1Ac than those reaching it, despite age or the presence of complications. The results of regression analysis showed that the strongest predictors of costs growth were the number of admissions, presence of complications and insulin treatment. It was also demonstrated that the mean medical cost per patient with uncomplicated DM T2 on insulin therapy was 38.5 thousand RUR, which was comparable to the cost per patient with complications, receiving other glucose-lowering treatment (37.0 thousand RUR).

Conclusion.

Costs for patients with DM complications are considerably higher than those for patients without complications. Therefore, the key point in controlling the growth of the DM economic burden is to minimise and/or prevent the development of DM complications, which could be achieved by timely DM diagnosis and appropriate glucose-lowering therapy.

1. IDF Diabetes Atlas. 6th Edition. Available from: http://www.idf.org/diabetesatlas

2. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2015 г. и перспективы развития // Сахарный диабет. – 2015. – Т. 18. – №3 – C. 5-22. [Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation. Diabetes mellitus. 2015;18(3):5-22. (In Russ)] doi: 10.14341/DM201535-22

3. Сунцов Ю.И., Болотская Л.Л., Маслова О.В., и др. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации // Сахарный диабет. – 2011. – Т. 14. – №1 – C. 15-19. [Suntsov YI, Bolotskaya LL, Maslova OV, Kazakov IV. Epidemiology of diabetes mellitus and prognosis of its prevalence in the Russian Federation. Diabetes mellitus. 2011;14(1):15-19. (In Russ)]. doi: 10.14341/2072-0351-6245

4. Ng CS, Lee JYC, Toh MPHS, Ko Y. Cost-of-illness studies of diabetes mellitus: A systematic review. Diabetes Res Clin Pract. 2014;105(2):151-163. doi: 10.1016/j.diabres.2014.03.020

5. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. PharmacoEconomics. 2015;33(8):811-831. doi: 10.1007/s40273-015-0268-9

6. Lipska KJ, Ross JS, Van Houten HK, et al. Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010. JAMA. 2014;311(22):2331. doi: 10.1001/jama.2014.6316

7. Gregg EW, Li Y, Wang J, et al. Changes in Diabetes-Related Complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514-1523. doi: 10.1056/NEJMoa1310799

8. Atanasov PK, Chan JC, Gagliardino JJ, et al. International Diabetes Management Practice Study (Idmps): Resource Use Associated With Type 2 Diabetes In Africa, Middle East, South Asia, Eurasia and Turkey. Value Health.2015;18(7):A619. doi: 10.1016/j.jval.2015.09.2165

9. Фармакоэкономика и фармакоэпидемиология – практика приемлемых решений / Ред. В.Б. Герасимов, А.Л. Хохлов, О.И. Карпов. – М.: Медицина, 2005. [Farmakoekonomika i farmakoepidemiologiya – praktika priemlemykhresheniy. Ed by V.B. Gerasimov, A.L. Khokhlov, O.I. Karpov. Moscow: Meditsina; 2005. (In Russ)]

10. Приказ Министерства здравоохранения Российской Федерации от 28 декабря 2012 г. № 1581н «Об утверждении стандарта первичной медико-санитарной помощи при инсулиннезависимом сахарном диабете». [PrOrder of the Ministry of Health of Russian Federation on 28 December 2012. N1581n “Ob utverzhdenii standarta pervichnoy mediko-sanitarnoy pomoshchi pri insulinnezavisimom sakharnom diabete”. (In Russ)] Доступно: http://www.rg.ru/2013/06/20/minzdrav-prikazy-dok.html#attachments

11. Государственный реестр предельных отпускных цен. [Russian Federation State Register of limiting selling prices. (In Russ)] Доступно: http://grls.rosminzdrav.ru/

12. Постановление Правительства РФ от 18 октября 2013 г. N 932 «О программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2014 год и на плановый период 2016 и 2016 годов». [Order of the Gouvernment of Russian Federation on 18 October 2013. N932 “O programme gosudarstvennykh garantiy besplatnogo okazaniya grazhdanam meditsinskoy pomoshchi na 2014 god i na planovyy period 2015 i 2016 godov”. (In Russ)]Доступно: http://ivo.garant.ru/document?id=70379406&byPara=1

13. Приказ Федерального фонда ОМС от 14 ноября 2013 г N 229 «Об утверждении «Методических рекомендаций по способам оплаты специализированной медицинской помощи в стационарных условиях и в дневных стационарах на основе групп заболеваний, в том числе клинико-статистических групп (КСГ) и клинико-профильных групп (КПГ) за счет средств системы обязательного медицинского страхования». [Order of the Federal Obligatory Medical Insurance Fund on 14 November 2013. N229 “Ob utverzhdenii “Metodicheskikh rekomendatsiy po sposobam oplaty spetsializirovannoy meditsinskoy pomoshchi v statsionarnykh usloviyakh i v dnevnykh statsionarakh na osnove grupp zabolevaniy, v tom chisle kliniko-statisticheskikh grupp (KSG) i kliniko-profil’nykh grupp (KPG) za schet sredstv sistemy obyazatel’nogo meditsinskogo strakhovaniya”. (In Russ)] Доступно: http://ivo.garant.ru/document?id=70418710&byPara=1

14. Годовой отчет 2013. Пенсионный фонд Российской Федерации. [Godovoy otchet 2013. Pensionnyy fond Rossiyskoy Federatsii. (In Russ)] Доступно: http://2014.pfrf.ru/userdata/presscenter/docs/godotchet_2013.pdf

15. С 1 апреля социальные пенсии выросли на 17,1%, трудовые пенсии – на 1,7%, ЕДВ – на 5%. Пенсионный фонд Российской Федерации, 31.03.2014. [S 1 aprelya sotsial’nye pensii vyrosli na 17,1%, trudovye pensii – na 1,7%, EDV –na 5%. Pension fond ща Russian Federation, 31.03.2014. (In Russ)] Доступно: http://www.pfrf.ru/press_center/~2014/03/31/2426

16. Динамика расходов и количества оплаченных дней пособий по временной нетрудоспособности по обязательному социальному страхованию за 2005-2011 годы. Фонд социального страхования РФ. [Dinamika raskhodov ikolichestva oplachennykh dney posobiy po vremennoy netrudosposobnosti po obyazatel’nomu sotsial’nomu strakhovaniyu za 2005-2011 gody. Social Insurance Fund of Russian Federation. (In Russ)] Доступно:http://fss.ru/ru/statistics/47775.shtml

17. Среднемесячная номинальная начисленная заработная плата работников по полному кругу организаций в целом по экономике по субъектам Российской Федерации за 2000-2014 гг. Федеральная служба государственной статистики. [Srednemesyachnaya nominal’naya nachislennaya zarabotnaya plata rabotnikov po polnomu krugu organizatsiy v tselom po ekonomike po subektam Rossiyskoy Federatsii za 2000-2014 gg. Federal State Statistics Service. (In Russ)] Доступно: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/wages/

18. Национальные счета. Федеральная служба государственной статистики. [Natsional’nye scheta. Federal’naya sluzhba gosudarstvennoy statistiki. (In Russ)] Доступно:http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/accounts/#; Трудовые ресурсы. Федеральная служба государственной статистики. [Trudovye resursy. Federal’naya sluzhba gosudarstvennoy statistiki. (In Russ)]Доступно: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/wages/labour_force/

19. Дедов И.И., Шестакова М.В., Александров А.А. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (٦-й выпуск) // Сахарный диабет. – 2013. – Т. 16. – №1S. – C. 1-120. [Dedov II, Shestakova MV, Aleksandrov AA, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1-120. (In Russ)] doi: 10.14341/DM20131S1-121

20. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета ٢ типа» // Сахарный диабет. – 2011. – Т. 14. – №1. – C. 95-105. [Dedov II, Shestakova MV, Ametov AS, et al. Consensus statement by a panel of experts of the Russian Association of Endocrinologists (RAE) on initiation and intensification of hypoglycemic therapy for type 2 diabetes mellitus. Diabetes mellitus. 2011;14(1):95-105. (In Russ)] doi: 10.14341/2072-0351-6256

21. Белоусов Д.Ю., Афанасьева Е.В. Базальные аналоги инсулина в контроле сахарного диабета 2 типа // Качественная клиническая практика. – 2014. – №1. – С. 3-13. [Belousov DU, Afanasyeva EV. Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects. Good clinical practice. 2014;(1):3-13. (In Russ)]

22. Сунцов Ю.И., Дедов И.И. Государственный регистр больных сахарным диабетом – основная информационная система для расчета экономических затрат государства на сахарный диабет и их прогнозирование // Сахарный диабет. – 2005. – Т. 8. – №2. – C.2-5. [Suntsov YI, Dedov II. Gosudarstvennyy registr bol’nykh sakharnym diabetom – osnovnayainformatsionnnaya sistema dlya rascheta ekonomicheskikh zatratgosudarstva na sakharnyy diabet i ikhprognozirovanie. Diabetes mellitus. 2005;8(2):2-5. (In Russ)] doi: 10.14341/2072-0351-5773

23. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2014;45(7):S13-S17. doi: 10.1007/s00125-002-0859-9

24. Liebl А, Khunti K, Orozco-Beltran D, et al. Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review. Clin Med Insights Endocrinol Diabetes. 2015:13. doi: 10.4137/cmed.s20906

25. Banerji MA, Dunn JD. Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes. Am Health Drug Benefits. 2013;6(7):382-392.

26. Juarez DT, Goo R, Tokumaru S, et al. Association Between Sustained Glycated Hemoglobin Control and Healthcare Costs. Am J Pharm Benefits. 2013;5(2):59-64.

27. Alva ML, Gray A, Mihaylova B, et al. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32(4):459-466. doi: 10.1111/dme.12647

28. Gray A. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320(7246):1373-1378. doi: 10.1136/bmj.320.7246.1373

29. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358(24):2545-2559. doi: 10.1056/NEJMoa0802743

30. Khunti K, Wolden ML, Thorsted BL, et al. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417. doi: 10.2337/dc13-0331

31. Калашникова М.Ф., Белоусов Д.Ю., Сунцов Ю.И. и др. Фармакоэпидемиологический анализ потребления сахароснижающих лекарственных средств у больных сахарным диабетом 2 типа в городе Москве // Сахарный диабет. – 2015. – Т. 18. – №2. – C.32-46. [Kalashnikova MF, Belousov DY, Suntsov YI, Kantemirova MA, Dedov II. Pharmacoepidemiological and pharmacoeconomic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow. Diabetes mellitus. 2015;18(2):32-46. (In Russ)] doi: 10.14341/DM2015232-46

32. Norton E. The Business of Intensive Insulin Therapy for Type 2 Diabetes Patients: Where It all Began for Me. J Diabetes Sci Technol. 2009;3(6):1521-1523. doi: 10.1177/193229680900300635